Trial Profile

Phase II, randomized, drouble-blind, placebo-controlled trial investigating the efficacy and safety of org 3236 [etonogestrel] tablets in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etonogestrel (Primary)
Indications Benign prostatic hyperplasia
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

10 Aug 2008 Patient numbers changed from planned number 240 to actual number 16 as reported by ClinicalTrials.gov.
10 Aug 2008 Status changed from recruiting to terminated as reported by ClinicalTrials.gov.
10 Aug 2008 The expected completion date for this trial is now 1 Aug 2008 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com